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Abstract
Haemanthus coccineus extracts (HCE) have traditionally been used to treat a variety of diseases, like febrile colds or asthma. Since new thera-
peutic options against inflammatory processes are still urgently needed, we aimed to pharmacologically characterise the anti-inflammatory
potential of HCE in vitro and in vivo and to identify the underlying bioactive component(s). The action of HCE on oedema formation and leuco-
cyte infiltration were analysed in two murine models of inflammation (dermal oedema induced by arachidonic acid and croton oil; kidney injury
caused by unilateral ureteral obstruction). The interaction of leucocytes with endothelial cells (ECs) as well as the activation parameters of these
two cell types were analysed. Moreover, the nuclear factor jB (NFjB) pathway was investigated in detail in ECs. Using different fractions of
HCE, the bioactive principle was identified. In vivo, HCE (450 mg/kg orally or 2 mg/kg intraperitoneally) inhibited oedema formation, leucocyte
infiltration and cytokine synthesis. In vitro, HCE (100–300 ng/ml) blocked leucocyte-EC interaction as well as the activation of isolated
leucocytes (cytokine synthesis and proliferation) and of primary ECs (adhesion molecule expression). HCE suppressed NFjB-dependent gene
transcription in the endothelium, but did not interfere with the NFjB activation cascade (IjB degradation, p65 nuclear translocation and NFjB
DNA-binding activity). The alkaloid narciclasine was elucidated as the bioactive compound responsible for the anti-inflammatory action of HCE.
Our study highlights HCE and its main alkaloid narciclasine as novel interesting approach for the treatment of inflammation-related disorders.
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Introduction
Activation of inflammatory processes is a physiologically protective
host response to tissue damage, infections or alterations caused by
malignant cells. However, in many chronic diseases, like atheroscle-
rosis, rheumatoid arthritis, asthma or chronic kidney disease, it con-
tributes to pathological conditions [1–3]. For most of these
inflammation-related disorders, the conventional treatment including
non-steroidal anti-inflammatory therapeutics, glucocorticoids or
immunosuppressives is not always effective and often causes severe
side effects. Therefore, new anti-inflammatory strategies are desper-
ately needed to improve the benefit-to-risk ratio of the treatment [4].
Initial steps of inflammation involve cytokine-mediated activation of
leucocytes [5] and of the vascular endothelium [6]. In response to
pro-inflammatory mediators, such as tumour necrosis factor alpha
(TNFa), the vascular endothelium strongly increases its expression of
the cell adhesion molecules intercellular cell adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and endothe-
lial leucocyte adhesion molecule-1 (E-selectin) [7, 8], a crucial step
for the extravasation of leucocytes into the inflamed tissue [9, 10].
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The interaction between leucocytes and the vascular endothelium has
been recognised as an attractive target for the therapy of numerous
disorders and diseases including excessive inflammatory responses
[11].
Plant-derived natural products are still a very important source of
therapeutically effective agents [12–14]. Natural compound struc-
tures provide enormous chemical diversity and highly specific bio-
chemical activity that make them valuable lead structures [15].
Haemanthus coccineus extracts (HCE), especially preparations of the
bulbs, have been used in the traditional South African medicine as a
diuretic agent or for the treatment of inflammation-associated condi-
tions including febrile colds, asthma, ulcers or wounds [16–18].
Plants of the Amaryllidaceae family are well-known for their variety of
pharmacologically active alkaloids [19]. Narciclasine (Narc), an iso-
carbostyril alkaloid found in the bulbs of H. coccineus, has previously
been shown to induce apoptosis in different tumour cell lines and to
be highly selective for cancer cells compared to non-cancerous cells
[20, 21].
In this study, we have suggested that HCE exerts profound anti-
inflammatory actions in vitro and in vivo by influencing endothelial
and immune cells leading to the attenuation of cytokine expression
and leucocyte extravasation. Moreover, we aimed to determine the
bioactive principle of the extract responsible for these effects.
Materials and methods
Compounds
Haemanthus coccineus extracts, extract fractions and Narc were kindly
provided by Dr. Willmar Schwabe GmbH & Co. KG (Karlsruhe, Ger-
many). The extract was prepared from dried bulbs of H. coccineus with
60% ethanol (w/w). Drug extract ratio was 50:1. The resulting HCE was
adjusted to a content of 2.2% Narc. The HCE was partitioned between
ethyl acetate and water. The dried ethyl acetate phase was subsequently
chromatographed through Sephadex LH-20 using 100% methanol as
eluent. From this separation, a crude Narc fraction was obtained. Crys-
tallisation of this fraction from methanol–acetone 1:1 lead to pure Narc.
The structure of the isolate was identified by MS and NMR. The remain-
ing fractions (Narc-free) from Sephadex LH-20 separation were further
separated with reversed-phase HPLC to give complex basic alkaloid
fractions (Dragendorff-positive reaction, thin-layer chromatography) that
could not be further fractionated. Haemanthus coccineus extracts, its
fractions and Narc were solubilised in DMSO (Sigma-Aldrich, Taufkir-
chen, Germany). Stock solutions at 30 mg/ml (HCE), 10 mg/ml (extract
fractions) and 3 mM (Narc) were stored at 20°C. Substances were
diluted in growth medium (concentrations as described in the respective
passages) without exceeding a final DMSO concentration of 0.1%.
Recombinant human TNFa was from PeproTech (Hamburg, Germany),
formaldehyde (16%, methanol-free, ultra pure) was from Polysciences
(Eppelheim, Germany). Heparin, 2-mercaptoethanol, croton oil, arachi-
donic acid (AA), dexamethasone (DEX), Tween 80, concanavalin A
(Con A), lipopolysaccharide (LPS) and fluorescein isothiocyanate (FITC)-
dextran (40 kD) were purchased from Sigma-Aldrich. [3H]-thymidine
was from GE Healthcare (Freiburg, Germany). PEG 400, agar and
acetone were obtained from Merck (Darmstadt, Germany). Tepoxalin
(TEP, Zubrin 100 mg) was purchased from Essex-Tierarznei (Munich,
Germany) and Isofluran CP was obtained from CP-Pharma (Burgdorf,
Germany).
Animals
All animal care and experimental procedures were in accordance with
the guidelines of the German Animal Protection Law and were approved
by the Ethics Review Committee for Laboratory Animals of the District
Government of Darmstadt (Germany) and Karlsruhe (Germany), respec-
tively. C57BL/6 mice were purchased from Charles River Laboratories
(Sulzfeld, Germany). Naval Medical Research Institute (NMRI) mice
were provided by Janvier Labs (Le Genest-Saint-Isle, France).
Cell culture
Primary human umbilical vein endothelial cells (HUVECs) were purchased
from PELOBiotech (Martinsried, Germany). The human microvascular
endothelial cell line CDC/EU.HMEC-1 [22] was kindly provided by the Cen-
tres for Disease Control and Prevention (CDC, Atlanta, GA, USA) and was
used until passage 30. HMECs were exclusively used in the THP-1 adhe-
sion and permeability assay. Endothelial cells (ECs) were cultured in EC
growth medium (PELOBiotech), which was supplemented with 10%
heat-inactivated foetal bovine serum (FBS, Biochrom, Berlin, Germany),
100 U/ml penicillin (PAN-Biotech, Aidenbach, Germany), 100 lg/ml
streptomycin (PAN-Biotech) and 0.25 lg/ml amphotericin B (PAN-Bio-
tech) under constant humidity at 37°C in an atmosphere containing 5%
CO2. Human neutrophil granulocytes were purified from peripheral blood
of healthy volunteers using CD15 MicroBeads (Miltenyi, Bergisch Glad-
bach, Germany). The monocyte-like cell line THP-1 (ACC-16) was kindly
provided by the Leibniz Institute for German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany) and cultured as
described by Fischer et al. [23]. Lymphocytes were isolated from spleens
of male C57BL/6 mice by gentle disruption and homogenization of the
spleens and final density gradient centrifugation with Lymphodex (Frese-
nius, Bad Homburg, Germany). Lymphocytes were washed two times in
Hank’s Balanced Salt Solution (HBSS) and were cultured in complete
RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% heat-inacti-
vated FBS (Sigma-Aldrich), 2 mM glutamine (Sigma-Aldrich), 100 U/ml
penicillin, 100 lg/ml streptomycin, 0.25 lg/ml amphotericin B (antibi-
otic/antimycotic solution, Sigma-Aldrich) and 50 lM 2-mercaptoethanol
under constant humidity at 37°C in an atmosphere containing 5% CO2.
Mouse peritoneal macrophages were gained by injecting male NMRI mice
intraperitoneally with 45 mg thioglycollate (Sigma-Aldrich) in 1.5 ml ster-
ile H2O. Four days later, cells were recovered from 12 animals by perito-
neal lavage with 5 ml HBSS containing heparin (0.04%). Activated
macrophages were collected by centrifugation, washed two times with
HBSS and cultured under the same conditions as murine lymphocytes.
Dermal ear oedema model
A local inflammation in male NMRI mice was induced by the epicutane-
ous application of croton oil (2.5 lg/ll) or AA (82 nM), each in ace-
tone, to the right ear. To the left ear, only acetone was applied.
Haemanthus coccineus extracts was administered orally at doses rang-
ing from 50 to 450 mg/kg 1 hr before croton oil or AA was applied.
After six (croton oil) or after one (AA) hour, the animals were killed.
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Tissue plugs were punched out uniformly from each ear and plug
weight was determined. The reduction of oedema formation was calcu-
lated as [1  (Wt/Wc) 9 100], with Wt and Wc representing the weight
difference between plugs from the left and the right ear in treated or
control mice. Dexamethasone-treated (0.3 mg/kg) or tepoxalin-treated
(100 mg/kg) mice were used as positive control group. For visualising
the presence of granulocytes in the tissue, mice ear paraffin sections
(4 lm) were stained with a naphthol-AS-D-chloroacetate-esterase kit
(Sigma-Aldrich) in accordance with the manufacturer’s protocol. The
intensity of staining was evaluated microscopically per high power field
(HPF, 4009).
Unilateral ureteral obstruction model
Obstruction of the left ureter was performed in 2-month-old male
C57BL/6 mice as reported previously [24]. Sham-operated mice served
as control groups. Mice were divided into four groups: sham-operated
animals receiving vehicle (PBS), sham-operated mice treated with HCE,
unilateral ureteral obstruction (UUO) mice receiving PBS and UUO mice
treated with HCE. Vehicle or HCE (2.0 mg/kg) was intraperitoneally
administered to mice daily. Kidneys and plasma were analysed at day
three after ligation of the left ureter.
Renal immunohistochemistry
Serial sections (4 lm) of paraffin-embedded samples were processed
for immunohistochemical studies using rat anti-mouse F4/80 antise-
rum (macrophage marker; AbD Serotec, Puchheim, Germany) and
horseradish peroxidase/3,30-diaminobenzidine techniques [25, 26].
Incubation with the primary antibody was performed overnight at
4°C. Counterstaining was performed with Meyer’s Haematoxylin
(Sigma-Aldrich). The specificity of immunostaining was confirmed by
omitting the primary antibody and by non-immune serum/unspecific
IgG. Infiltrating macrophages were counted in 15 randomly selected
non-overlapping HPFs (4009) of renal sections and calculated per
field using Soft Imaging System (Olympus, Hamburg, Germany).
Quantitative polymerase chain reaction
Total RNA from mouse kidneys was isolated using TRI reagent (Sigma-
Aldrich) as described previously [25] and reversely transcribed using
the Verso cDNA synthesis Kit (Thermo Fisher Scientific, Schwerte, Ger-
many). cDNA was amplified using TaqMan Gene Expression assays.
Probes for mouse Tnf (Mm_00443260_g1), chemokine (C-C motif)
ligand (Ccl2, Mm00441242_m1) and glyceraldehyde-3-phosphate dehy-
drogenase (Gapdh, Mm03302249_g1) were purchased from Life Tech-
nologies (Darmstadt, Germany). Amplification and detection were
performed with an ABI prism 7500 Sequence Detection System (Life
Technologies). The threshold cycle for the gene of interest was normal-
ized to that of Gapdh.
CCL2 plasma protein level
Plasma samples were used to determine CCL2 protein levels by mouse-
specific ELISA (R&D Systems, Wiesbaden, Germany) in accordance to
the manufacturer’s protocol in duplicates.
Synthesis of pro-inflammatory cytokines in
murine peritoneal exudate cells
Mouse peritoneal activated macrophages were gained as described in
the section cell culture. About, 4 9 105 cells per well were cultured in
96-well plates (TPP, Trasadingen, Switzerland). Cytokine release was
assayed by an ELISA as described previously [27]. Briefly, cells were
pre-treated with HCE for 30 min., and then cytokine production was
stimulated by the addition of LPS from Escherichia coli (1 lg/ml) for
24 hrs. After cell lysis, the amount of synthesised pro-inflammatory
cytokines was quantified in supernatants with commercially available
ELISA kits for TNFa (R&D Systems), interleukin (IL)-6 (R&D Systems)
and IL-b (R&D Systems) in accordance to the manufacturer’s protocol.
Lymphocyte proliferation
Lymphocytes were gathered from murine spleens as described in the
section cell culture. Proliferation assays with murine lymphocytes were
performed as described previously [27]. Briefly, lymphocytes (105 cells
per well) were cultured in 96-well plates (Greiner Bio-One, Frickenhau-
sen, Germany) and treated as described. As mitogens Con A or LPS
from Salmonella typhosa were used at final concentration of 2.5 lg/ml.
Cells were pulse-labelled with [3H]-thymidine (0.5 lC/25 ll per well)
during the final 6 hrs of the 72 hrs incubation period and then har-
vested onto fibre glass filters type G-10 (Berthold Detection Systems,
Pforzheim, Germany) using the semiautomatic cell counter H 110 (Bert-
hold Detection Systems). Incorporation of radioactively labelled thymi-
dine was determined directly by the position-sensitive proportional
counter LB284RA (Berthold Detection Systems).
THP-1 adhesion assay
HMECs were cultured to confluence in 24-well plates (VWR, Darmstadt,
Germany) and exposed to HCE as described. Cell-TrackerTM Green-
labelled (10 lM; Life Technologies) THP-1 cells were allowed to adhere
on a confluent HMEC monolayer for 1 hr. Non-adherent THP-1 cells
were removed by washing three times with pre-warmed PBS (containing
Ca2+ and Mg2+). After lysis, fluorescence was analysed at 535 nm using
a Varioskan Flash plate reader (Thermo Fisher Scientific, Langensel-
bold, Germany).
Neutrophil granulocyte adhesion assay
Neutrophil granulocytes were added to confluent HUVECs that were
pre-treated as indicated and allowed to adhere for 30 min. After lysis,
myeloperoxidase activity, an enzyme solely expressed in neutrophils,
was measured in the supernatants as described previously [28].
Flow cytometric analysis
Human umbilical vein ECs were trypsinized, formalin-fixed (4%, metha-
nol-free), washed and incubated with FITC-labelled anti-CD54 (ICAM-1)
antibody (BIOZOL, Eching, Germany), FITC-labelled anti-CD106 (VCAM-1)
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1023
J. Cell. Mol. Med. Vol 19, No 5, 2015
antibody (Becton Dickinson, Heidelberg, Germany) or PE-labelled anti-
CD62E (E-selectin) antibody (Becton Dickinson). Stained HUVECs were
analysed by flow cytometry (FACSCanto II or FACSVerse, Becton Dickin-
son) [28]. Apoptotic cell rates were quantified by measuring the subdip-
loid DNA content and analysed by flow cytometry (FACSCanto II)
according to the method of Nicoletti et al. [29].
Dual luciferase nuclear factor jB reporter gene
assay
The assay was performed as described previously [28]. Briefly, HUVECs
(70–80% confluent) were transiently cotransfected with the firefly lucifer-
ase reporter vector pGL4.32[luc2P/nuclear factor (NF)jB-RE/Hygro] (Pro-
mega Corp., Heidelberg, Germany) and the Renilla luciferase control
reporter vector (determination of transfection efficiency) pGL4.74[hRluc/
TK] (Promega) at a ratio of 10:1 using the Targefect-HUVEC kit (Target-
ingsystems, El Cajon, CA, USA) and cultured for 18 hrs. Then, cells were
treated as described, lysed and the NFjB promoter activity was measured
by the Dual-Luciferase Reporter Gene assay (Promega) according to the
manufacturer’s instructions. Luciferase activity was detected using a Bert-
hold Orion II Luminometer (Berthold Detection Systems).
Western blot analysis
Human umbilical vein EC cell lysates were prepared as reported previ-
ously [28]. Proteins were separated by SDS-PAGE and transferred to
polyvinylidene difluoride membranes (Bio-Rad Laboratories, Munich,
Germany) by tank electroblotting. Membranes were blocked with bovine
serum albumin (BSA, Sigma-Aldrich). The following primary antibodies
were used: mouse monoclonal b-tubulin (1:1000; Santa Cruz Biotech-
nology, Heidelberg, Germany), rabbit polyclonal anti-IjBa (1:1000;
Santa Cruz Biotechnology), rabbit polyclonal anti-phospho (T180/Y182)-
p38 (1:1000; Cell Signaling/New England Biolabs, Frankfurt am Main,
Germany), rabbit polyclonal anti-p38 (1:1000; Cell Signaling/New Eng-
land Biolabs), mouse monoclonal anti-phospho (T202/Y204)-ERK1/2
(1:1000; Cell Signaling/New England Biolabs), rabbit polyclonal anti-
ERK1/2 (1:1000; Cell Signaling/New England Biolabs), rabbit monoclonal
anti-phospho (Y705)-STAT3 (1:1000; Cell Signaling/New England Biol-
abs) and mouse monoclonal anti-STAT3 (1:1000; Cell Signaling/New
England Biolabs). For detection, mouse monoclonal anti-b-actin
(1:25,000; Sigma-Aldrich), goat-anti-mouse (1:2000; Santa Cruz Bio-
technology), and goat-anti-rabbit (1:2000; Santa Cruz Biotechnology)
antibody labelled with horseradish-peroxidase were used.
NFjB p65 translocation
Human umbilical vein ECs were cultured until confluence on collagen-
coated l-slides (Ibidi, Martinsried, Germany) and treated as indicated.
Cells were washed, fixed with AccustainTM (Sigma-Aldrich), permeabi-
lized by 0.2% Triton X-100 (Merck), blocked in 0.2% BSA and incu-
bated with an anti-NFjB p65 (Santa Cruz Biotechnology) primary and
AlexaFluor 488-linked secondary antibody (Molecular Probes/Life Tech-
nologies). Fluorescence microscopy was performed on a Zeiss Observer
Z1 (Zeiss, Oberkochen, Germany). Quantification of p65 NFjB nuclear
intensity was performed with ImageJ version 1.43u (National Institutes
of Health, Bethesda, MD, USA).
Electrophoretic mobility shift assay
Nuclear protein extracts were prepared from HUVECs, and electropho-
retic mobility shift assay was performed as described previously [28].
Cell viability assay
Human umbilical vein ECs were treated as indicated and metabolic
activity was determined by the CellTiter-Blue assay (Promega) as
described previously [30]. Viable cells retain the ability to reduce the
non-fluorescent resazurin into resorufin, which is highly fluorescent.
Fluorescence (ex: 560 nm; em: 590 nm) intensity was detected by a
SPECTRAFluor Plus plate reader (Tecan, Crailsheim, Germany).
Macromolecular permeability assay
HMECs were used to investigate macromolecular (FITC-dextran, 40 kD)
endothelial permeability in a two compartment system (Transwell
inserts; Corning, Wiesbaden, Germany). The assay was performed as
reported previously [31].
Broth microdilution susceptibility assay
Antimicrobial activity was evaluated by determining the minimum inhibi-
tory concentration (MIC), i.e. the lowest concentration of HCE and Narc
that prevents visible growth of a microorganism in a broth microdilution
susceptibility test, following guidelines set by the Clinical and Labora-
tory Standards Institute (CLSI) [32]. All MICs were determined in tripli-
cates and quality control was performed according to CLSI
recommendations.
Statistical analysis
The numbers of independently performed experiments (N) are stated in
the respective figure legends. In the case that nothing else is men-
tioned, bar graph data are expressed as means  SEM. Statistical
analyses were performed with the software Prism (version 5.04; Graph-
Pad Software, San Diego, CA, USA). For evaluation of three or more
groups one-way ANOVA followed by Dunnett’s significance correction test
or Tukey’s post-hoc test was used. P ≤ 0.05 were considered as statis-
tically significant.
Results
HCE reduces oedema formation and neutrophil
infiltration in vivo
An in vivo model of an acute and local inflammation was used to
investigate the anti-inflammatory potential of HCE. In this model, ear
oedema was induced in mice by two different pro-inflammatory com-
pounds: (i) In the croton oil-induced model, mice were treated orally
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with three different dosages of HCE (50, 150, 450 mg/kg) 1 hr before
croton oil was epicutaneously applied. The highest dosage signifi-
cantly decreased the ear weight differences (65%) between
inflamed and non-inflamed ears, which clearly indicates a diminished
oedema formation (Fig. 1A). Notably, HCE was as potent as the glu-
cocorticoid DEX. (ii) As a second pro-inflammatory agent, AA was
used to evoke ear oedema formation. Oral pre-treatment with HCE
(1 hr before AA was applied) dose-dependently attenuated the swell-
ing of the AA-treated ear compared to the control ear (Fig. 1B). Again,
the anti-inflammatory potency of HCE (450 mg/kg) was comparable
to that of an established non-steroidal anti-inflammatory drug (tepox-
alin). Interestingly, no anti-inflammatory effect was observed when
HCE (250 lg) was applied topically to the ear (data not shown).
Indeed, the number of neutrophil granulocytes in the ear tissue was
significantly reduced (50%) by HCE (450 mg/kg) in the croton oil
model (Fig. 1C). These data clearly hint towards a profound anti-
inflammatory potential of HCE, which is associated with a reduced
infiltration of neutrophils.
HCE attenuates macrophage extravasation and
CCL2 production after UUO
In a second in vivo model, which uses unilateral ureteral obstruction
to trigger inflammatory events in murine kidneys, HCE (2 mg/kg/d for
3 days) was applied intraperitoneally. As shown in Figure 2A, HCE
blocked the UUO-induced infiltration of macrophages into tubulointer-
stitial regions of the obstructed kidney. Moreover, we analysed the
levels of CCL2, an important chemoattractant for macrophages also
known as monocyte chemotactic protein-1. Haemanthus coccineus
extracts attenuated the synthesis of CCL2 mRNA in the kidney by
44% (Fig. 2B) and inhibited the rise of this chemokine evoked by
UUO in the blood by 86% (Fig. 2C). Our results indicate that treat-
ment with HCE strongly diminishes macrophage infiltration in the
UUO model by decreasing CCL2 levels.
HCE strongly blocks the release of pro-
inflammatory cytokines and the proliferation of
leucocytes in vitro
We investigated whether HCE can interfere with the activation of mac-
rophages and/or lymphocytes. LPS-activated macrophages from the
murine peritoneum were treated in vitro with HCE. The extract con-
centration-dependently suppressed the secretion of the pro-inflam-
matory cytokines TNFa (Fig. 3A), IL-6 (Fig. 3B), and IL-1b (Fig. 3C).
The IC50 values were calculated as 152, 497, and 517 ng/ml, respec-
tively. Interestingly, we could also observe a slight decrease of TNFa
secreted by macrophages during renal injury (data not shown).
Besides macrophages, HCE also affects isolated murine lymphocytes.
Both the proliferation of T cells, induced by Con A (Fig. 3D), and the
proliferation of B cells, caused by LPS (Fig. 3E), were strongly attenu-
ated by HCE in a concentration-dependent manner. These data sug-
gest that HCE can block the inflammation-associated activation of
macrophages and lymphocytes.
HCE reduces the adhesion of leucocytes to the
endothelium and the expression of EC adhesion
molecules
Since leucocyte extravasation is tightly controlled by the endothelium,
we investigated the influence of HCE on ECs. We found that the adhe-






















































































Fig. 1 HCE diminishes oedema formation
in vivo. The HC extract (50–450 mg/kg)
was administered orally to mice 1 hr
before croton oil (A) or arachidonic acid
(B) was applied epicutaneously. After six
(A) or after one (B) hour, the ear weight
as a measure for oedema formation was
determined. Dexamethasone (0.3 mg/kg;
A) as well as tepoxalin (100 mg/kg; B)
were used as positive control groups.
N = 8, per group; *P < 0.05 versus con-
trol (Co); n.s. = not significantly different
versus dexamethasone (DEX; A) or tepox-
alin (TEP; B). (C) Quantification of neutro-
phil count per HPF. N (Co) = 22, N
(HCE) = 30, N (Co + croton oil) = 28, N
(HCE + croton oil) = 36; *P ≤ 0.05.
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concentration-dependently inhibited by HCE, which was exclusively
applied to ECs (Fig. 4A). Also the adhesion of freshly isolated human
neutrophils onto a TNFa-activated monolayer of primary human ECs
was clearly reduced by HCE (Fig. 4B). Adhesion events are mediated
by the up-regulation of EC adhesion molecules [33]. Thus, we studied
the action of HCE on the TNFa-triggered cell surface expression of
ICAM-1 (Fig. 4C), VCAM-1 (Fig. 4D), and E-selectin (Fig. 4E).
Haemanthus coccineus extracts strongly suppressed the up-regula-
tion of all three adhesion molecules in a clear concentration-depen-
dent manner. IC50 values were calculated as 305 ng/ml for ICAM-1,
231 ng/ml for VCAM-1, and 117 ng/ml for E-selectin. Moreover, we
proved that the applied concentrations of HCE had no cytotoxic
effects on ECs. Neither the metabolic activity (Fig. S1A) nor the apop-
totic cell rate (Fig. S1B) were affected at concentrations used in our
experimental settings (10–300 ng/ml). Taken together, HCE strongly
inhibits leucocyte adhesion to ECs by preventing the expression of EC
adhesion molecules.
HCE downregulates NFjB-dependent gene
expression, but does not influence the activation
cascade of endothelial NFjB
The expression of adhesion molecules is strongly regulated by the
pro-inflammatory transcription factor NFjB. The impact of HCE on
the NFjB-dependent promoter activity was investigated in ECs by
a luciferase-based NFjB reporter gene assay. As shown in Fig-
ure 5A, HCE concentration-dependently decreased NFjB promoter
activity in TNFa-activated HUVECs. We have suggested that HCE
might interfere with the activation cascade of NFjB. However, we
could not detect any influence of HCE, neither on the TNFa-
induced degradation of the NFjB inhibitor IjBa (Fig. 5B), nor on
the nuclear translocation of the NFjB subunit p65 (Fig. 5C), or
the DNA-binding activity of NFjB (Fig. 5D). In summary, these
findings provide evidence that HCE suppresses NFjB-dependent
gene expression without interfering with the canonical activation
cascade of this transcription factor.
The anti-inflammatory effect of HCE can clearly
be assigned to the isocarbostyril alkaloid Narc
We aimed at identifying the bioactive compound(s) responsible for
the anti-inflammatory action of HCE. Thus, we tested nine fractions
obtained from the ethyl acetate extract of H. coccineus for their ability
to affect the TNFa-induced ICAM-1 expression, which was used as
robust read-out parameter. All subfractions, which contain (besides
other compounds) the basic alkaloids of HCE, were applied at
300 ng/ml, but did not affect ICAM-1 expression (Fig. 6A). In con-
trast, the isolated non-basic isocarbostyril alkaloid Narc, the main
alkaloid of HCE, significantly reduced ICAM-1 expression with an IC50
value as low as 50 nM (Fig. 6B). These findings highlight Narc as the
A
CB
Fig. 2 HCE exhibits anti-inflammatory
activities in the UUO model. (A) Represen-
tative immunohistochemical staining of
infiltrated macrophages (brown colour) in
renal sections from HCE-treated mice after
UUO (UUO+HCE), untreated mice (UUO),
sham-operated mice (Co) or sham-oper-
ated mice by followed HCE treatment
(HCE). Scale bar indicates 100 lm. Quan-
tification of the infiltrated macrophages in
the renal injured tissue was assessed per
high power field. N (Co) = 15, N
(UUO) = 14, N (HCE) = 15, N
(UUO+HCE) = 15; *P ≤ 0.05. Determina-
tion of mRNA (B) or plasma protein levels
(C) of renal CCL2 in total kidney homo-
genates. After UUO mice were treated with
HCE (UUO + HCE) or left untreated
(UUO). Sham-operated mice (Co) and
sham-operated mice with subsequent HCE
treatment (HCE) served as control groups.
N (Co) = 3, N (HCE) = 3, N (UUO) = 3, N
(UUO + HCE) = 5. *P ≤ 0.05; n.s. = not
significantly different.
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major bioactive compound responsible for the anti-inflammatory
action of HCE.
Discussion and conclusion
Limited efficacy and intolerable side effects of the available anti-
inflammatory agents, such as steroids, immunosuppressives, and
non-steroidal anti-inflammatory drugs, have constantly motivated an
intensive search for new compounds that inhibit the inflammatory
response [4]. Natural products have long been recognized as a key
source for the development of novel therapeutic strategies to treat
human disorders, including inflammatory diseases [34]. In this study,
we demonstrate for the first time that treatment with an extract from
bulbs of H. coccineus and its major ingredient, the isocarbostyril
alkaloid Narc, represent a novel and interesting anti-inflammatory
approach.
Inflammatory events are characterized by changes in vascular
permeability resulting in oedema formation. We clearly showed that
HCE exhibits a pronounced anti-inflammatory and anti-oedematogen-
ic activity in vivo, which was comparable to that of the glucocorticoid
DEX or the COX/LOX inhibitor tepoxalin. Only the oral administration
led to an anti-inflammatory action, the topical application of HCE was
not effective (data not shown). Thus, the systemic availability of
ingredients of HCE seem to be necessary for its in vivo activity against
local ear oedema. Interestingly, HCE seems not to interfere with endo-
thelial processes that regulate vascular barrier function, since macro-
molecular permeability was not altered by HCE (Fig. S2).
The most prominent action of HCE was the reduction in leucocyte
infiltration both in the ear oedema and in the kidney injury model
(UUO). This effect could in principle be evoked by an inhibition (i) of
leucocyte and/or (ii) of EC activation: (i) Local expression of the
chemokine CCL2 by immune or ECs of the injured kidney was
suppressed by HCE on mRNA as well as on plasma protein level. Fur-
thermore, HCE effectively inhibited the release of prominent
pro-inflammatory cytokines (TNFa, IL-6, and IL-1b) from (isolated
murine) macrophages and suppresses the proliferation of (isolated


















1 2 3 4 5 
HCE log [ng/ml] 
0 
120 
















1 2 3 4 5 
HCE log [ng/ml] 
0 


















1 2 3 4 5 
HCE log [ng/ml]  
120 




























HCE [ g/ml] –










































Fig. 3 HCE inhibits pro-inflammatory cyto-
kine synthesis and suppresses lymphocyte
proliferation in vitro. Murine macrophages
were pre-incubated with HCE (3 ng/ml–
10 lg/ml) for 30 min. and then activated
with LPS (1 lg/ml) for 24 hrs. The con-
centrations of TNFa (A), IL-6 (B) and IL-
1b (C) in the cell culture were analysed
by ELISA. N = 3. (D and E) Lymphocytes
isolated from mice spleens were treated
with HCE (100 ng/ml–1 lg/ml) and acti-
vated with Con A (2.5 lg/ml; D) or LPS
(2.5 lg/ml; E) for 72 hrs. Subsequently,
cells were pulse-labelled with [methyl-3H]
thymidine (0.5 lC/25 ll per well) for
6 hrs. Thymidine uptake was measured
and lymphocyte proliferation was evalu-
ated in counts per minute (cpm). N = 4;
*P ≤ 0.05 versus control.
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different types of leucocytes. (ii) The up-regulation of EC adhesion
molecules is a hallmark of inflammatory processes and crucial for
leucocyte extravasation and tissue infiltration [35]. Haemanthus coc-
cineus extracts strongly inhibited the cell surface expression of all
investigated adhesion molecules (ICAM-1, VCAM-1, and E-selectin).
Interestingly, some disorders that have traditionally been treated with
HCE in South Africa (e.g. asthma) are associated with inflammatory
processes. Thus, we for the first time provide evidence for the rational
basis of this usage, since we found that HCE effectively prevents both
leucocyte and EC activation. Besides the anti-inflammatory action of
HCE, we also investigated a potential antimicrobial effect of the
extract. This might be of importance since many immunosuppressive
therapies show infections as side effects [36, 37]. However, no anti-
bacterial activity of HCE or Narc could be observed against relevant
human pathogens at the given concentrations that reveal anti-inflam-
matory activity (Table S1).
Regarding the underlying mechanism, we demonstrated that HCE
does not affect the pro-inflammatory signal transducers p38 MAPK,
ERK1/2, and STAT3 (Fig. S3), but significantly inhibits NFjB-depen-
dent gene transcription. The transcription factor NFjB is crucially
involved in the pro-inflammatory activation of both leucocytes and
ECs, since NFjB response elements are part of the promoter region
of many cytokines and adhesion molecules [38]. Surprisingly, none
of the key players of the canonical NFjB activation cascade (IjB deg-
radation, nuclear p65 translocation, NFjB DNA binding) were altered.
Since NFjB DNA-binding can still occur, but NFjB-dependent gene
expression is blocked, one could speculate that HCE could interfere
with mRNA production, stability, or shuttling. This hypothesis is
based on one of our former studies: We could show that flavopiridol,
a potent inhibitor of cyclin-dependent kinases (CDKs), blocks NFjB
promoter activity and the expression of NFjB-dependent genes. In






Fig. 4 HCE strongly reduces leucocyte
adhesion by blocking the expression of
endothelial adhesion molecules. (A) After
HCE pre-treatment (10–300 ng/ml for
30 min.) HMECs were treated with TNFa
(10 ng/ml) for 6 hrs. Cell-TrackerTM Green-
labelled THP-1 monocytic cells were
added (3 9 105 cells per well) and were
allowed to adhere for 1 hr. The fluores-
cence of adhered monocytic THP-1 cells
was measured (ex: 485 nm; em: 535 nm).
N = 4; *P ≤ 0.05, versus TNFa. (B) Con-
fluent primary endothelial cells were left
untreated or were pre-incubated with HCE
(0.1 and 0.3 lg/ml) for 30 min. Then they
were treated with TNFa (10 ng/ml) for
24 hrs. Human neutrophil granulocytes
were added (105 cells per well) and were
allowed to adhere for 45 min. To deter-
mine the amount of adhered neutrophils
the activity of myeloperoxidase was mea-
sured. N = 3; *P ≤ 0.05 versus TNFa. (C
and D) Adhesion molecule expression on
the endothelial cell surface was deter-
mined by flow cytometry. HUVECs were
either left untreated or were pre-incubated
with HCE (10 ng/ml–10 lg/ml) for
30 min. Afterwards, cells were treated
with TNFa (10 ng/ml) for 24 hrs (C,
ICAM-1; D, VCAM-1) or for 6 hrs (E, E-se-
lectin). N = 3.
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stage of the NFjB activation cascade. Instead, we found that flavopir-
idol was able to alter transcription elongation in the nucleus by inhibi-
tion of CDK9 [39].
As a future perspective, it would be interesting to investigate
whether HCE interferes with the death receptor (DR) pathway.
Dumont et al. recently reported that Narc induces cell-specific apop-
tosis by inducing the initial caspases of DR pathways for the cell
death surface receptor FAS and DR4 [40]. Besides tumour cells, also
ECs express DR4, which binds to its ligand TNF-related apoptosis-
inducing ligand. Activation of this receptor has been reported to par-
ticipate in the regulation of EC activation including apoptosis, differen-
tiation, inflammation, and proliferation [41].
By screening different fractions of HCE, we could show that
basic alkaloids (e.g. coccine, haemanthamin, lycorine and monta-
nine) are not active. We identified the non-basic alkaloid Narc to
be responsible for the anti-inflammatory effect of HCE. Many stud-
ies report that Narc possesses profound anti-cancer activities in
vivo and in vitro [21, 42, 43]. Regarding inflammation, few reports
have shown that Narc can protect against adjuvant-induced arthri-
tis in mice [44–46]. In accordance with our data, Yui et al.
observed that Narc attenuates cytokine synthesis in murine macro-
phages. Interestingly, at least three direct targets of Narc have
been suggested: In the 1970s, the alkaloid was discussed as inhib-
itor of protein synthesis by interfering with ribosomes of rabbit
reticulocytes [47] or HeLa cells [48, 49]. Moreover, Narc can
induce stress fibre formation in cancer cells by activating the small
GTPase RhoA [50]. In 2010, it was reported that Narc binds to
and inhibits the transcription elongation factor eEF1A in melanoma
cells [51]. Leucocytes and ECs have as yet not been evaluated in
this context. Nevertheless, regarding our results on the transcrip-
tion factor NFjB (inhibition of gene expression without blocking
NFjB activity), we could speculate that Narc might inhibit eEF1A
also in ECs. However, we could not observe a global reduction in
the protein synthesis resulting in cytotoxicity. Furthermore, from
our permeability measurements, we do not have hints that Narc
influences the EC shape and, thus, the cytoskeleton. In contrast to
all these targets, we currently investigate the hypothesis that the




Fig. 5 HCE suppresses TNFa-triggered
NFjB promoter activity but does not affect
canonical NFjB activation cascade. (A)
Confluent HUVECs were cotransfected
with an NFjB reporter vector (firefly lucif-
erase) and a control vector (Renilla lucif-
erase). 24 hours after transfection, cells
were pre-treated with HCE (100 or
300 ng/ml) for 30 min. TNFa (10 ng/ml)
was applied for 5.5 hrs. A Dual-Lucifer-
ase Reporter Gene assay was used to
analyse NFjB-dependent reporter gene
expression, which is expressed as ratio of
firefly luciferase/Renilla luciferase activity.
N = 4; *P ≤ 0.05 versus TNFa. (B) Levels
of IjBa and b-actin were assessed by
Western blot analysis. One representative
out of three independently performed
experiments is shown, each. (C) The
translocation of NFjB p65 subunit into
the nucleus was visualized by immunocy-
tochemistry and fluorescence microscopy.
The median nuclear fluorescence intensity
was analysed. N = 3; n.s. = not signifi-
cantly different. (D) Nuclear extracts were
prepared from HUVEC lysates and subse-
quently analysed for their NFjB DNA-bind-
ing activity via radioactive gel shift assay
followed by densitometric analysis. N = 3;
n.s. = not significantly different.
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In summary, the results of our study provide a solid scientific
explanation for the traditional use of extracts of H. coccineus as her-
bal remedy for the treatment of inflammation-related diseases. More-
over, we showed that HCE interferes with inflammatory processes in
a dual manner: it affects both leucocytes and ECs. Haemanthus coc-
cineus extracts inhibits leucocyte tissue infiltration by blocking the
interaction of leucocytes with the endothelium, it attenuates leucocyte
activation (proliferation as well as cytokine production), and
decreases the up-regulation of adhesion molecules in the endothe-
lium. These effects are based on the inhibition of NFjB-dependent
gene expression. Taken together, our study suggests the use of HCE
and its main alkaloid Narc as novel and promising approach to treat
inflammatory conditions.
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Additional Supporting Information may be found in the online
version of this article:
Figure S1 Cell viability is affected by HCE only at very high concentra-
tions.
Figure S2 HCE does not affect thrombin receptor-activating
peptide (TRAP)-induced endothelial hyperpermeability.
Figure S3 HCE does not interfere with endothelial MAPK or
STAT3 signalling pathway.
Table S1 Minimum inhibitory concentration (MIC) of HCE and narci-
clasine against relevant human pathogens.
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